ALNA stock +3.16% intraday on 252,311,606 shares NASDAQ Mar 19 2026: watch cash

ALNA stock is trading higher intraday after heavy activity on the NASDAQ, with the share price at $0.075 and volume at 252,311,606 shares. The move follows broader interest in small-cap biotech names and reflects speculative flows rather than fresh company disclosures. Investors should note the intraday range from $0.06 to $0.146, the recent EPS of -0.64, and the PE of -0.12, all of which shape short-term trading and risk for longer-term holders.

ALNA stock intraday movers

ALNA (Allena Pharmaceuticals, Inc.) is among today’s most active NASDAQ names, trading on the United States exchange in USD. The stock opened at $0.0641, closed previously at $0.0727, and is up 3.16% intraday. The large volume spike to 252,311,606 shares suggests momentum trading; momentum traders should check liquidity and bid/ask spreads before entering.

Price action and trading metrics for ALNA stock

The intraday low and high are $0.06 and $0.146 respectively, showing wide price swings. Market cap reports at $0.00 in some feeds because shares outstanding data is limited. Average volume figures are not reported, so compare today’s 252,311,606 to recent sessions before sizing positions. Short-term volatility is clear; day traders should set strict stops.

Fundamentals and valuation for ALNA stock

Allena Pharmaceuticals operates in Healthcare, Biotechnology, and reports negative earnings. Key metrics: EPS -0.64, PE -0.12, cash per share $0.92, book value per share $0.58, current ratio 2.11. These figures point to a cash-backed biotech with ongoing operating losses and limited revenue. The low price-to-book of 0.13 signals market skepticism but also a tangible-book cushion.

Meyka stock grade and technicals for ALNA

Meyka AI rates ALNA with a score out of 100: 62.55 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, industry peers, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. The grade reflects a mixed profile: solid cash relative to equity but recurring operating losses. This grade is informational and not financial advice.

Catalysts, risks and ALNA stock sector context

Catalysts include trial updates for ALLN-346 and regulatory milestones; these events can swing the stock. Risks include continued cash burn, trial failure, and low liquidity in normal sessions. The biotech sector in the United States remains sensitive to trial news and funding; small-cap biotech volatility often outpaces broader Healthcare moves. Monitor company releases and wider sector flows.

ALNA stock forecast, price targets and analyst view

Meyka AI’s forecast model projects a 12-month price target of $0.12, implying an upside of 60.00% versus the current $0.075. Practical price-target range for traders: conservative $0.05 (downside -33.33%), base $0.12 (+60.00%), bull $0.20 (+166.67%). Forecasts are model-based projections and not guarantees. For company details see Allena Pharmaceuticals website and follow broader market coverage such as the recent WSJ sector piece source. For real-time quotes visit our internal page ALNA on Meyka.

Final Thoughts

Intraday action on ALNA stock shows heavy volume and wide price swings, reflecting speculative interest in Allena Pharmaceuticals on NASDAQ in the United States. Key facts: market price $0.075, intraday range $0.06–$0.146, volume 252,311,606, EPS -0.64, cash per share $0.92, current ratio 2.11. Meyka AI’s forecast model projects a 12-month target of $0.12, implying a 60.00% upside from today’s price; this assumes successful clinical progress and stable funding. Traders should balance that upside against clear risks: ongoing operating losses, trial risk, and episodic liquidity. Our Meyka grade (B, HOLD) reflects a mixed fundamental view. Use strict risk management, verify company filings, and watch catalysts before sizing positions. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.